RAGE plays key role in diabetic retinopathy: a review

被引:0
|
作者
ZhiWen Lu
Bin Fan
YunZhi Li
YiXin Zhang
机构
[1] The Second Hospital of Jilin University,Department of Ophthalmology
[2] Nanguan District,undefined
关键词
RAGE; AGE; NF-κB; HMGB1; Diabetic retinopathy; Inflammation; Neovascularization; Treatment;
D O I
暂无
中图分类号
学科分类号
摘要
RAGE is a multiligand receptor for the immunoglobulin superfamily of cell surface molecules and is expressed in Müller cells, vascular endothelial cells, nerve cells and RPE cells of the retina. Diabetic retinopathy (DR) is a multifactorial disease associated with retinal inflammation and vascular abnormalities and is the leading cause of vision loss or impairment in older or working-age adults worldwide. Therapies aimed at reducing the inflammatory response and unnecessary angiogenesis can help slow the progression of DR, which in turn can save patients’ vision. To maximize the efficacy and minimize the side effects, treatments that target key players in the pathophysiological process of DR need to be developed. The interaction between RAGE and its ligands is involved in a variety of cytopathological alterations in the retina, including secretion of inflammatory factors, regulation of angiogenesis, oxidative stress, structural and functional changes, and neurodegeneration. In this review, we will summarize the pathologic pathways mediated by RAGE and its ligand interactions and discuss its role in the progression of diabetic retinopathy to explore potential therapeutic targets that are effective and safe for DR.
引用
收藏
相关论文
共 50 条
  • [1] RAGE plays key role in diabetic retinopathy: a review
    Lu, Zhiwen
    Fan, Bin
    Li, Yunzhi
    Zhang, Yixin
    BIOMEDICAL ENGINEERING ONLINE, 2023, 22 (01)
  • [2] AGEs, RAGE, and Diabetic Retinopathy
    Zong, Hongliang
    Ward, Micheal
    Stitt, Alan W.
    CURRENT DIABETES REPORTS, 2011, 11 (04) : 244 - 252
  • [3] AGEs, RAGE, and Diabetic Retinopathy
    Hongliang Zong
    Micheal Ward
    Alan W. Stitt
    Current Diabetes Reports, 2011, 11 : 244 - 252
  • [4] The RAGE axis in early diabetic retinopathy
    Barile, GR
    Pachydaki, SI
    Tari, SR
    Lee, SE
    Donmoyer, CM
    Ma, WC
    Rong, LL
    Buciarelli, LG
    Wendt, T
    Hörig, H
    Hudson, BI
    Qu, W
    Weinberg, AD
    Yan, SF
    Schmidt, AM
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46 (08) : 2916 - 2924
  • [5] The role of inflammation in diabetic retinopathy: a review
    Taurone, S.
    Ralli, M.
    Nebbioso, M.
    Greco, A.
    Artico, M.
    Attanasio, G.
    Gharbiya, M.
    Plateroti, A. M.
    Zamai, L.
    Micera, A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (20) : 10319 - 10329
  • [6] AGE and RAGE inhibitors in the treatment of diabetic retinopathy
    Bhatwadekar, Ashay
    Stitt, Alan W.
    EXPERT REVIEW OF OPHTHALMOLOGY, 2007, 2 (01) : 105 - 120
  • [7] NRF2 plays a protective role in diabetic retinopathy in mice
    Xu, Zhenhua
    Wei, Yanhong
    Gong, Junsong
    Cho, Hongkwan
    Park, James K.
    Sung, Ee-Rah
    Huang, Hu
    Wu, Lijuan
    Eberhart, Charles
    Handa, James T.
    Du, Yunpeng
    Kern, Timothy S.
    Thimmulappa, Rajesh
    Barber, Alistair J.
    Biswal, Shyam
    Duh, Elia J.
    DIABETOLOGIA, 2014, 57 (01) : 204 - 213
  • [8] NRF2 plays a protective role in diabetic retinopathy in mice
    Zhenhua Xu
    Yanhong Wei
    Junsong Gong
    Hongkwan Cho
    James K. Park
    Ee-Rah Sung
    Hu Huang
    Lijuan Wu
    Charles Eberhart
    James T. Handa
    Yunpeng Du
    Timothy S. Kern
    Rajesh Thimmulappa
    Alistair J. Barber
    Shyam Biswal
    Elia J. Duh
    Diabetologia, 2014, 57 : 204 - 213
  • [9] Sphingolipid metabolism plays a key role in diabetic peripheral neuropathy
    Lili Song
    Rui Han
    Hongqing Yin
    Jingfang Li
    Yue Zhang
    Jiayi Wang
    Zhen Yang
    Junwei Bai
    Maojuan Guo
    Metabolomics, 18
  • [10] Emerging role of ferroptosis in diabetic retinopathy: a review
    Wang, Ruohong
    Rao, Suyun
    Zhong, Zheng
    Xiao, Ke
    Chen, Xuhui
    Sun, Xufang
    JOURNAL OF DRUG TARGETING, 2024, 32 (04) : 393 - 403